

DATE: December 20, 2005 SHEET _1_ of _1_

DOCUMENT NUMBER CATION COUNTRY OR SUB LATION			_							•				
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) U.S.PATENT DOCUMENTS EXAMINER PATENT NUMBER SSUE PATENTEE CLASS CLASS DATE FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION FOREIGN PATENT NUMBER PATENT OF PUBLISHED FOREIGN PATENT APPLICATION FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION OTHER DOCUMENT NUMBER PATENT OFFICE CLASS CLASS VES NO DATE PATENT OFFICE CLASS CLASS VES NO DATE PATENT OFFICE CLASS CLASS VES NO OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication) OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication) A2 Roberts et al., "Bioequivalence of a New Sustained-Release Formulations of Valproate Modified-Release Granules, Compared with Existing Sustained-Release Formulations of Valproate in lealthy volunteers", Biopharmaceutics & Drug Disposition, 17 (2), 175-182, (1996) EXAMINER Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.														
(Use several sheets if necessary) U.S.PATENT DOCUMENTS EXAMINER PATENT NUMBER DATE PATENTEE CLASS CLASS DATE FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION DOCUMENT NUMBER PUBLICATION COUNTRY OR PATENT OFFICE CLASS CLASS VES NO DATE PATENT OFFICE CLASS CLASS VES NO OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication) OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication) A1 Dulac et al., "Bioequivalence of a New Sustained-Release Formulation of Sodium Valproate, Valproate Modified-Release Granules, Compared with Existing Sustained-Release Formulations After Once or Twice-Daily Administration", Pharmacouterapy, 25 (1), 3514, (2005) A2 Roberts et al., "Epilim chrono: a multidose, crossover comparison of two formulations of valproate in healthy volunteers", Biopharmaceutics & Drug Disposition, 17 (2), 175-182, (1996) EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.										APPLICANT Y. Qiu et al.				
U.S.PATENT DOCUMENTS EXAMINER NITIAL PATENT NUMBER DATE PATENTEE CLASS CLASS DATE		(I le		vera	lehor	ate if	nec	0000	rv)	FILING DATE	GRO	UP	•	
U.S.PATENT DOCUMENTS EXAMINER INITIAL PATENT NUMBER DATE PATENTEE CLASS CLASS DATE FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION DOCUMENT NUMBER CATION COUNTRY OR PATENT OFFICE CLASS CLASS VES NO DATE PATENT OFFICE CLASS CLASS VES NO VES NO CLASS CLASS VES NO DATE OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication) OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication) OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication) A1 Duac et al., "Bioequivalence of a New Sustained-Release Formulation of Sodium Valproate, Valproate Modified-Release Granules, Compared with Existing Sustained Release Formulations After Once- or Twice-Daily Administration", Pharmacotherapy, 25 (1), 3541, (2005) A2 Roberts et al., "Epitim chrono: a multidose, crossover comparison of two formulations of valproate in healthy volunteers", Biopharmaceutics & Drug Disposition, 17 (2), 175-182, (1996) EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	107 OFF 1 00								• 37	February 2, 2004	161	5		
FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION DOCUMENT NUMBER CATION COUNTRY OR PATENT OFFICE CLASS CLASS YES NO DATE PATENT OFFICE CLASS CLASS YES NO DATE PATENT OFFICE CLASS CLASS YES NO CLASS YES NO DATE PATENT OFFICE CLASS CLASS	(37 CFR 1.98	(D))										-		·
FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION DOCUMENT NUMBER								U	J.S.PATENT !	DOCUMENTS		•		
FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION DOCUMENT NUMBER			1						ISSUE		<u> </u>	SUB	FILI	NG
DOCUMENT NUMBER CATION COUNTRY OR PATENT OFFICE CLASS SUB LATION YES NO OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication) OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication) Julia	INITIAL			PAT	ENT	NUM	<u> 1BEI</u>	Ŗ	DATE	PATENTEE	CLASS	CLASS		
DOCUMENT NUMBER CATION COUNTRY OR PATENT OFFICE CLASS SUB LATION YES NO OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication) OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication) Julia			┦—	Ш	_	-	╀	4	ļ	· · · · · · · · · · · · · · · · · · ·				
DOCUMENT NUMBER CATION COUNTRY OR PATENT OFFICE CLASS SUB LATION YES NO OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication) OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication) Julia	•	-	+-	Н	\vdash		+-	╁╌┤			-	ļ	ļ	
DOCUMENT NUMBER CATION COUNTRY OR PATENT OFFICE CLASS SUB LATION YES NO OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication) OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication) Julia				-		+-	+-	╁┈┤			-		<u> </u>	
DOCUMENT NUMBER CATION COUNTRY OR PATENT OFFICE CLASS SUB LATION YES NO OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication) OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication) Julia		<u> </u>	+	\vdash	\vdash	<u> </u>	╈	\dagger				1	 	
DOCUMENT NUMBER CATION COUNTRY OR PATENT OFFICE CLASS SUB LATION YES NO OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication) OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication) Julia		<u></u>	-									<u></u>	·	
OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication) A1		F(ORE	EIG	N P	ATE	NT	OR		FOREIGN PATENT	APPLICA	ATION		
DATE PATENT OFFICE CLASS CLASS YES NO OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication) OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication) A1 Dulac et al., "Bioequivalence of a New Sustained-Release Formulation of Sodium Valproate, Modified-Release Granules, Compared with Existing Sustained-Release Formulations After Once or Twice-Daily Administration", Pharmacotherapy, 25 (1), 35-41, (2005) Roberts et al., "Epilim chrono: a multidose, crossover comparison of two formulations of valproate in healthy volunteers", Biopharmaceutics & Drug Disposition, 17 (2), 175-182, (1996) EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.				٠										
OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication) A1 Dulac et al., "Bioequivalence of a New Sustained-Release Formulation of Sodium Valproate, Valproate Modified-Release Granules, Compared with Existing Sustained-Release Formulations After Once or Twice-Daily Administration", Pharmacotherapy, 25 (1), 35-41, (2005) Roberts et al., "Epilim chrono: a multidose, crossover comparison of two formulations of valproate in healthy volunteers", Biopharmaceutics & Drug Disposition, 17 (2), 175-182, (1996) EXAMINER //sis Ghali/ EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			ט ן	JCU	MEN	II N	JME	BER			01.400			
A1			+				Т	т-	DATE	PATENT OFFICE	CLASS	CLASS	YES	INO
A1			╁	Н	+	+	+	╁				 		<u> </u>
A1			+-	Н	\vdash	┪	†	┼		W-14-10-10-10-10-10-10-10-10-10-10-10-10-10-		 		
A1			1				\top							† —
A1														
A1				Ш										
A1						L_			<u> </u>			1		
Modified-Release Granules, Compared with Existing Sustained Release Formulations After Once- or Twice-Daily Administration", Pharmacotherapy, 25 (1), 35-41, (2005) Roberts et al., "Epilim chrono: a multidose, crossover comparison of two formulations of valproate in healthy volunteers", Biopharmaceutics & Drug Disposition, 17 (2), 175-182, (1996) EXAMINER //sis Ghali/ EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			ОТ	HE	R D	ocı	JMI	ENT	S (Including A	uthor, Title, Date, Place	of Publica	tion)		
Modified-Release Granules, Compared with Existing Sustained Release Formulations After Once- or Twice-Daily Administration", Pharmacotherapy, 25 (1), 35-41, (2005) Roberts et al., "Epilim chrono: a multidose, crossover comparison of two formulations of valproate in healthy volunteers", Biopharmaceutics & Drug Disposition, 17 (2), 175-182, (1996) EXAMINER //sis Ghali/ EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		A1	T	Du	lac et	al. "	Bioe	ouiv	alence of a New S	Sustained-Release Formulatio	n of Sodiun	Valproate \	Valoros	nte
Twice-Daily Administration", Pharmacotherapy, 25 (1), 35-41, (2005) Roberts et al., "Epilim chrono: a multidose, crossover comparison of two formulations of vaproate in healthy volunteers", Biopharmaceutics & Drug Disposition, 17 (2), 175-182, (1996) EXAMINER //sis Ghali/ EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	/I C /													iic
healthy volunteers", Biopharmaceutics & Drug Disposition, 17 (2), 175-182, (1996) EXAMINER	/I.G./			Tw	ice-D	aily /	٩dm	inistr	ration", Pharmaco	therapy, 25 (1), 35-41, (2005)			
EXAMINER //sis Ghali/ EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		A2		Rol	berts	et al.,	"Ep	ilim	chrono: a multido	se, crossover comparison of	two formula	ations of vap	roate in	
/Isis Ghali/ EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	/I.G./_		-	hea	ilthy y	/olun	teers	", Bi	opharmaceutics &	Drug Disposition, 17 (2), 1	75-182, (19 <u>9</u>	96)		
/Isis Ghali/ EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		 		-								•		
/Isis Ghali/ EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		-	+	\vdash										
/Isis Ghali/ EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		 	+											
/Isis Ghali/ EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	EXAMINER		1		•					DATE CONSIDERED				
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.				1	lsis (Ghali	1				/Isis Ghal	1		
				on c	onsi	dered	. Dr				nd		· 	
(Form PTO-1449)	not conside	red. In	clud	е со	py of	this	form	with	n next communic	ation to applicant.	<u>_</u> _			
										•	(F	orm PTO-14	149)	•

OIPE C. TRADEMENT

			Slieer _ I _ OI _
FORM PTO-1449 (Rev. 2032)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 6437.US.C4	Serial No. 10/770,290
7	INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Applicant Qiu, et al.	
	(Use several sheets if necessary)	Filing Date February 2, 2004	Group 1615

		PTMI

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date (if appro.)
I /I.G./	4,369,172	01/18/83	Schor et al.			
	4,699,927	10/18/87	Deboeck			
	4,913,906	04/03/90	Friedman et al			
	4,988,731	01/29/91	Meade			
	5,009,897	04/23/91	Brinker et al			
1	5,017,613	05/21/91	Aubert, et al.		<u> </u>	
	5,019,398	05/28/91	Daste			
	5,055,306	10/08/91	Barry et al			
	5,169,642	12/08/92	Brinker et al			
	5,185,159	02/09/93	Aubert et al		<u> </u>	
	5,212,326	05/18/93	Meade		1	
V /I.G./	5,589,191	12/31/96	Ukigaya et al	i	<u> </u>	<u> </u>

FOREIGN PATENT DOCUMENTS

Г		Document Number	Date	Name	Class	Subdass	Translation (Yes No)
Ī	/l.G./	94/27587	08.12.94	wo			1
П		00/37055	29.06.00	wo			
П	L.	00/45793 A1	08/10/00	wo		<u> </u>	
П		98/47491	29.10.98	wo			
	1	0 430 287 B2	06/05/91	EP			
Y	/I.G./	0 141 267 B1	08/05/87	EP		1	

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

/I.G./	Bialer et al., Int. J. Ph	Bialer et al., Int. J. Pharmaceutics, 20: 53-63 (1984)					
/I.G./	Bialer et al., Biopharr	Bialer et al., Biopharmaceutics and Drug Disposition, 6: 401-411 (1985)					
/I.G./	Bialer et al., Israel J. I	Bialer et al., Israel J. Med. Sci., 20: 46-49 (1984)					
/I.G./		ed Release Formulations of Anticonvulsant Medications Clinical Therapeutic Advantages, CNS Drugs 2000 Sept 14 (3): 203-212					
/I.G./	Freitag, et al., "Depak	Freitag, et al., "Depakote ER in Migraine Prophylaxis", Abstract No. S07.003, Nuerology 54 April 2000 (Suppl 3), page A14.					
/I.G./	Physicians' Desk Refe	Physicians' Desk Reference, (Web Version), 2001, Depakote ER, published by The Medical Economics Company					
/I.G./	"Metabolism of Antie (1984)	"Metabolism of Antiepiliptic Drugs", 143-151, R.H. Levy, Ed. Raven Press, New York					
/I.G.	Physicians' Desk Refe published by Medical	Physicians' Desk Reference. 54th Edition, 2000, Depakene Capsules, pp. 426-427, published by Medical Economic Company, Inc.					
/I.G/	Physicians' Desk Reference. 54th Edition, 2000, Depakote Tablets, pp. 431-437, published by Medical Economic Company, Inc.						
/I.G./		Package insert for Depakote® ER dated August 2000					
EXAMINER /Isis Ghali/ DATE CONSIDERED 07/25/2007							

Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw Line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date (if appro.)
/I.G./	5,593,690	01/18/83	Schor et al.			
/I.G./	5,593,694	01/14/97	Akiyama et al.			
/I.G./	5,980,913	11/09/99	Ayer et al.			
/l.G./	6,077,542	06/20/00	Sherman	1 .		·
/I.G./	6,150,410	11/21/00	Engh, et al.		1	
FO	REIGN PATENT DOCL	IMENTS		·		

	FOREIGN FATENT DOCUMENTS						
		Document Number	Date	Name	Class	Subclass	Translation (Yes No)
ļ							

OTH	ER DOCUMENTS (Including	Author, Title, Date, Pertinent Pages, Etc.)					
/I.G./		al., "Extended Release Formulations of Anticonvulsant Medications Clinical Therapeutic Advantages", CNS Drugs, New Zealand, 2000, 14/3 (203-212)					
/I,G./	Abstract of Bialer, et a	Abstract of Bialer, et al., "Criteria to Assess in Vivo Performance and Bioequivalence of Generic Controlled-Release Formulations of Carbamazepine", Epilepsia, United States, 1998, 39/5 (513-519)					
/I.G./	Sodium Tablets, a Dela	Abstract of Chun, et al., "Multiple-dose Evaluation of the Absorption Characteristics of Divalproex Sodium Tablets, a Delayed-Release Preparation of Valproate, in Healthy Volunteers", Clinical Drug Investigation, New Zealand, 1995, 10/1 (40-47)					
/I.G./		et al., "A Double Weibull Input Function Describes the Complex Absorption or al Sodium Valproate", Journal of Pharmaceutical Sciences, United States, (4)					
/I.G./	Intravenous Infusion A	Abstract of Hussein, et al., "Pharmacokinetics of Valproate after Multiple-dose Oral and Intravenous Infusion Administration: Gastrointestinal-related Diurnal Variation", Journal of Clinical Pharmacology, United States, 1994, 34/7 (754-759)					
/I.G./	Abstract of Wilder, et a	Abstract of Wilder, et al., "Gastrointestinal Tolerance of Divalproex Sodium", Neurology, United States, 1983, 33/6 (808-811)					
/I.G.		al., "Twice-daily Dosing of Valproate with Divalproex", Clinical rapeutics, United States, 1983, 34/4 (501-504)					
I.G./	Colins, et al., "Depakor	Colins, et al., "Depakote CR: Biopharmaceutical and Pharmacokinetic Studies of a New Formulation for Once Daily Dosing", Neurology, Vol. 50(4), Supplement 4, April 1998, p. A426					
I.G./	Samara, et al., "Bioavailability of a Controlled-Release Formulation of Depakote", No. 3.053, Epilepsia, Vol. 38, Suppl. 8, 1997						
/I.G.	Cavanaugh, et al., "Effe Depakote Under Multip	ect of Food on the Bioavailability of a Controlled-Release Formulation of ple-Dose Conditions", No. 2.002, Epilepsia, Vol. 38, Suppl. 8, 1997					
EXAMINER	/Isis Ghali/	DATE CONSIDERED 07/25/2007					

Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw Line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.